Extract
We read with interest the real-world data of Nanzer et al. [1], looking at adrenal insufficiency (AI) in severe asthma patients taking oral corticosteroid-sparing anti-interleukin (IL)-5 therapy. They reported that 43% of patients apparently failed a short adrenocorticotropic hormone (ACTH) stimulation test associated with a median baseline morning serum cortisol of 86 nmol·L−1 and a median prednisolone dose of 5 mg. We would be interested to know the mean cortisol level after ACTH, as well as the percentage of patients who failed to achieve a post-ACTH level of 500 nmol·L−1 which is the accepted cut-off for impaired response [2, 3].
Abstract
Low dose ACTH stimulation test is more likely to detect adrenal insuffiency in patients being weaned off oral corticosteroids https://bit.ly/2XsMA3i
Footnotes
Conflict of interest: B. Lipworth reports equipment from GSK , grants, personal fees for advisory board work, consultancy and lectures, and non-financial support for meeting attendance from AstraZeneca and Teva, personal fees for consultancy from Lupin, Glenmark, Vectura, Dr Reddy and Sandoz, during the conduct of the study; grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim, grants and personal fees for advisory board work, consultancy and lectures from Mylan, grants and personal fees for advisory board work and consultancy from Sanofi Regeneron, outside the submitted work; and has a family member who is an employee of AstraZeneca.
Conflict of interest: R. Chan has nothing to disclose.
Conflict of interest: C.R.W. Kuo reports personal fees for meeting attendance from AstraZeneca, personal fees for meeting attendance and lectures from Chiesi, personal fees for advisory board work from Circassia, outside the submitted work.
- Received April 29, 2020.
- Accepted May 19, 2020.
- Copyright ©ERS 2020
LIBRARY USERS
Log in through your institution
Purchase access
